Back to News
Market Impact: 0.38
Compass Pathways Targets 2027 COMP360 Launch After Positive Phase III Depression Data
Source: marketbeat.com
Healthcare & BiotechCorporate Guidance & OutlookProduct Launches
Compass Pathways said it remains on track to complete a rolling New Drug Application submission for COMP360 in Q4 2026. The planned filing follows positive Phase III studies of its synthetic psilocybin treatment for treatment-resistant depression, a key regulatory milestone that could materially advance the company's lead asset.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
strongly positive
Sentiment Score
0.58
Ticker Sentiment
CMPS0.78
More News
- Elon Musk once said the Cybertruck would be Tesla’s ‘best product ever.’ Now he’s winding down production
- Elanco Shares Jump After Q3 Beat and Outlook Raise
- A ‘geologic freak’ called the Smackover may end America’s lithium dependence on China, and Big Oil is already there
- Investing in Prediction Markets Will Pay Off, DraftKings CEO Says
- Where's the growth? Legacy automakers face a tougher 2027 as costs rise, market tightens
- Moderna raises 2026 outlook as CEO says newer vaccines are gaining traction